Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine

Haematologica

Volumn 85, Issue 9, 2000, Pages 922-925

  Zinzani, P L ^a   Magagnoli, M ^a   Bendandi, M ^a   Tani, M ^a   Stefoni, V ^a   Cellini, C ^a   Poggi, S ^a   Piccioli, M ^a   Pileri, S ^a   Tura, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

2 CdA; 9 year follow up; HCL; Re treated patients

Indexed keywords

2 CHLORODEOXYADENOSINE; ALPHA INTERFERON; PENTOSTATIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; LEUKEMIA REMISSION; MALE; RECURRENCE RISK; RETREATMENT;

ADULT; AGED; CLADRIBINE; DISEASE-FREE SURVIVAL; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMAN; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGE; RECURRENCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033786707     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Recombinant leukocyte α-interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results
2. Treatment of hairy cell leukemia with recombinant alpha interferon: I. Quantitative study of bone marrow changes during the first months of treatment
3. Treatment of hairy cell leukemia with recombinant alpha 2 interferon
4. Treatment of hairy-cell leukaemia with alpha-interferon (α-IFN)
5. Results in hairy-cell leukemia patients treated with alpha-interferon: Predictive prognostic factors
6. Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin)
7. Pentostatin induces durable remissions in hairy cell leukemia
8. Clinical experience with 2'-deoxycoformycin
9. Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin
10. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine
11. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA)
12. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia
13. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: A report of 979 patients
14. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: Differences in response in patients with and without abdominal lymphadenopathy
15. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine
16. Long term outcome of patients with hairy cell leukemia treated with pentostatin
17. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse
18. Treatment of hairy-cell leukemia with cladribine: Response, toxicity, and long-term follow-up
19. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment
20. Relapse of hairy cell leukemia after 2-chlorodeoxy-adenosine: Long-term follow-up of the Northwestern University experience
21. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: A 5-year survey
22. Weekly administration of 2-chloro-deoxyadenosine in patients with hairy-cell leukemia: A new treatment schedule effective and safer in preventing infectious complications
23. Bone-marrow biopsy in hairy cell leukemia (HCL) patients. Histological and immunohistological analysis of 46 cases treated with different therapies
24. Non parametric estimation from incomplete observations
25. High complete remission rate in hairy cell leukemia treated with 2-chlorodeoxyadenosine
26. Retreatment with 2-CdA of progressed HCL patients
27. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine
28. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin
29. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias
30. Second cancer risk in hairy cell leukemia: Analysis of 350 patients
31. Second malignancies in patients with hairy cell leukemia in British Columbia: A 20-year experience
32. Pilot study of rituximab in refractory or relapsed hairy cell leukemia
33. Response in refractory hairy cell leukemia to a recombinant immunotoxin